<DOC>
	<DOC>NCT00834041</DOC>
	<brief_summary>This first open-label study in a pediatric population was designed to evaluate aliskiren safety and pharmacokinetics after single and multiple dosing in 6-17 year old children with hypertension.</brief_summary>
	<brief_title>A Study to Evaluate the Safety/Tolerability and Pharmacokinetics of Aliskiren in Hypertensive Pediatric and Adolescent Patients 6-17 Years of Age</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<criteria>Male or female, 617 years of age Documented history of hypertension as defined in National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents (2004) Must be ≥ 21.0 kg and ≤ 100.0 kg at randomization Able to safely wash out previous antihypertensive therapy for 12 weeks Body weight of &lt; 21 kg (45 lbs) or &gt; 100 kg (220 lbs) Inability to discontinue prior antihypertensive medication as required during the washout period Any clinically significant abnormalities or clinically noteworthy abnormal laboratory values Renal artery stenosis Current diagnosis of heart failure (NYHA Class IIIV) msSBP ≥ 25% above the 95th percentile for age, gender, and height at Visit 2 Second or third degree heart block with or without a pacemaker Atrial fibrillation or atrial flutter at Visit 1, or potentially life threatening or any symptomatic arrhythmia during the 12 months prior to Visit 1 Evidence of current symptomatic valvular disease Other protocoldefined inclusion/exclusion criteria applied to the study.</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>aliskiren</keyword>
	<keyword>pediatric</keyword>
	<keyword>hypertension</keyword>
	<keyword>pharmacokinetics (PK)</keyword>
	<keyword>pharmacodynamics (PD)</keyword>
	<keyword>plasma renin activity</keyword>
	<keyword>mini-tablet formulation</keyword>
</DOC>